missing translation for 'onlineSavingsMsg'
Få mere at vide
Få mere at vide
6,6-Dimethyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one, Mikromol™
Beskrivelse
6,6-Dimethyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one
Tekniske data
Tekniske data
| Kemisk navn eller materiale | 1-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-4,4-dimethyl-2-propyl-1H-furo[3,4-d]imidazol-6(4H)-one |
| CAS | 849206-43-5 |
| Analyt- eller komponentnavne | 1-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-4,4-dimethyl-2-propyl-1H-furo[3,4-d]imidazol-6(4H)-one |
| Forsendelsestilstand | Room Temperature |
| Molekylær formel | C24 H24 N6 O2 |
| Certificeringer/compliance | ISO 17025 |
| Synonym | 6,6-Dimethyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one, Olmesartan Medoxomil Imp. B (EP), 4H-Furo[3,4-d]imidazol-4-one, 3,6-dihydro-6,6-dimethyl-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 4H-Furo[3,4-d]imidazol-4-one, 3,6-dihydro-6,6-dimethyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI), 1-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-4,4-dimethyl-2-propyl-1H-furo[3,4-d]imidazol-6(4H)-one, Olmesartan Medoxomil RC A (USP), Olmesartan Medoxomil Related Compound A, Olmesartan Medoxomil Impurity B |
| InChI formel | InChI=1S/C24H24N6O2/c1-4-7-19-25-21-20(23(31)32-24(21,2)3)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13H,4,7,14H2,1-3H3,(H,26,27,28,29) |
| SMIL | CCCc1nc2c(C(=O)OC2(C)C)n1Cc3ccc(cc3)c4ccccc4c5nnn[nH]5 |
| IUPAC navn | 6,6-dimethyl-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]furo[3,4-d]imidazol-4-one |
| Vis mere |
Produkttitel
Ved at klikke på Send, anerkender du, at du kan blive kontaktet af Fisher Scientific med hensyn til den feedback, du har givet i denne formular. Vi deler ikke dine oplysninger til andre formål. Alle angivne kontaktoplysninger skal også vedligeholdes i overensstemmelse med vores Privatlivspolitik.
Ser du en mulighed for forbedring?